$DNTH
Dianthus Therapeutics, Inc. /DE/

2020 Q2 Form 10-Q Financial Statement

#000119312520135615 Filed on May 07, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2020 Q1 2019 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.400M $7.280M $5.920M
YoY Change 25.21% 25.3% 6.86%
% of Gross Profit
Research & Development $12.61M $13.96M $18.71M
YoY Change -6.13% 32.51% 51.01%
% of Gross Profit
Depreciation & Amortization $500.0K $493.0K $480.0K
YoY Change 8.7% 16.55% 33.33%
% of Gross Profit
Operating Expenses $20.01M $21.24M $24.64M
YoY Change 3.48% 29.93% 37.42%
Operating Profit -$21.24M -$24.64M
YoY Change 29.93% 37.41%
Interest Expense $930.0K $1.230M $1.400M
YoY Change -42.94% -19.08% 12.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$19.08M -$20.01M -$23.24M
YoY Change 7.74% 34.93% 39.33%
Income Tax
% Of Pretax Income
Net Earnings -$19.08M -$20.01M -$23.24M
YoY Change 7.75% 34.9% 39.32%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$481.7K -$508.4K -$594.5K
COMMON SHARES
Basic Shares Outstanding 39.48M 39.33M 38.99M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2020 Q1 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $176.5M $130.4M $145.7M
YoY Change 2.44% 2.44% 2.17%
Cash & Equivalents $136.3M $74.93M $65.07M
Short-Term Investments $40.20M $55.50M $80.70M
Other Short-Term Assets $3.400M $2.700M $4.100M
YoY Change -68.22% -65.38% 46.43%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $179.9M $133.1M $149.8M
YoY Change -1.7% -1.44% 3.11%
LONG-TERM ASSETS
Property, Plant & Equipment $9.100M $9.529M $9.891M
YoY Change -14.54% -10.44% -3.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.800M $1.800M $1.800M
YoY Change 0.0% -10.0% 0.0%
Total Long-Term Assets $10.80M $11.31M $11.67M
YoY Change -13.1% -10.35% -2.68%
TOTAL ASSETS
Total Short-Term Assets $179.9M $133.1M $149.8M
Total Long-Term Assets $10.80M $11.31M $11.67M
Total Assets $190.7M $144.4M $161.5M
YoY Change -2.43% -2.2% 2.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.700M $3.947M $2.812M
YoY Change 14.94% 31.13% -19.47%
Accrued Expenses $7.400M $8.756M $11.30M
YoY Change -2.52% 78.33% 63.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.40M $12.70M $14.12M
YoY Change 4.63% 60.39% 35.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.400M $6.300M $6.200M
YoY Change 8.47% 8.62% 416.67%
Total Long-Term Liabilities $6.400M $6.300M $6.200M
YoY Change 8.47% 8.62% 397.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.40M $12.70M $14.12M
Total Long-Term Liabilities $6.400M $6.300M $6.200M
Total Liabilities $16.80M $19.04M $20.32M
YoY Change 5.76% 39.09% 74.2%
SHAREHOLDERS EQUITY
Retained Earnings -$199.5M -$179.5M
YoY Change 69.71% 74.73%
Common Stock $324.5M $320.7M
YoY Change 29.03% 29.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $173.9M $125.4M $141.2M
YoY Change
Total Liabilities & Shareholders Equity $190.7M $144.4M $161.5M
YoY Change -2.43% -2.2% 2.67%

Cashflow Statement

Concept 2020 Q2 2020 Q1 2019 Q4
OPERATING ACTIVITIES
Net Income -$19.08M -$20.01M -$23.24M
YoY Change 7.75% 34.9% 39.32%
Depreciation, Depletion And Amortization $500.0K $493.0K $480.0K
YoY Change 8.7% 16.55% 33.33%
Cash From Operating Activities -$19.20M -$16.66M -$15.62M
YoY Change 27.74% 11.52% 23.67%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K $131.0K -$150.0K
YoY Change -96.46% -89.53% -96.55%
Acquisitions
YoY Change
Other Investing Activities $15.00M $25.53M -$5.570M
YoY Change -135.13% -322.39% -93.37%
Cash From Investing Activities $14.96M $25.40M -$5.730M
YoY Change -134.14% -299.47% -93.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 65.60M 1.124M 920.0K
YoY Change 8.02% 99.64% -295.74%
NET CHANGE
Cash From Operating Activities -19.20M -16.66M -15.62M
Cash From Investing Activities 14.96M 25.40M -5.730M
Cash From Financing Activities 65.60M 1.124M 920.0K
Net Change In Cash 61.36M 9.862M -20.43M
YoY Change 3163.83% -136.39% -79.87%
FREE CASH FLOW
Cash From Operating Activities -$19.20M -$16.66M -$15.62M
Capital Expenditures -$40.00K $131.0K -$150.0K
Free Cash Flow -$19.16M -$16.79M -$15.47M
YoY Change 37.84% 3.71% 86.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74933000
CY2020Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2019Q4 us-gaap Assets
Assets
161514000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1780000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9529000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9891000
CY2020Q1 us-gaap Assets
Assets
144441000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65071000
CY2020Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
55473000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
80658000
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2726000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4114000
CY2020Q1 us-gaap Assets Current
AssetsCurrent
133132000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
149843000
CY2020Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6337000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
6206000
CY2020Q1 us-gaap Liabilities
Liabilities
19040000
CY2019Q4 us-gaap Liabilities
Liabilities
20321000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
144441000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
161514000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3947000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2812000
CY2020Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
8756000
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11303000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12703000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14115000
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
39000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
39000
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
324505000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
320641000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
363000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
8000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199506000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-179495000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
125401000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19656000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14785000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13963000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10537000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7281000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5813000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
21244000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
16350000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
355000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-20011000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
355000
CY2020Q1 us-gaap Revenues
Revenues
0
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-21244000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16350000
CY2020Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
1233000
CY2019Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
1516000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-14834000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39364437
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
33422278
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
49000
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
49000
CY2019Q1 us-gaap Revenues
Revenues
0
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
141193000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1124000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2740000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
145648000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
563000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2577000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
134003000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2740000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2577000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
493000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
423000
CY2020Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-14000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-20011000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-14834000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1388000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5019000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1135000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-658000
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2547000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1636000
CY2020Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-131000
CY2019Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-4523000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16657000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14936000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
131000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1251000
CY2020Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
4974000
CY2020Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30500000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25395000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12731000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1124000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1124000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
563000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9862000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27104000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
66851000
CY2020Q1 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
6072000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
80658000
CY2019Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
312000
CY2019Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
18980000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60125000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76713000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33021000
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1138000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
563000
CY2019Q4 mgta Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
6516000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8756000
CY2019Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60300000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-76800000
CY2020Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
55110000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
363000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
55473000
CY2020Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
80650000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
29000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11303000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
586000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
660000
CY2020Q1 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
601000
CY2019Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
601000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1199000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3247000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
298000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2740000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2577000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
24200000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2020Q1 mgta Sublease Commencement Period
SubleaseCommencementPeriod
2018-06
CY2020Q1 mgta Sublease Expiration Period
SubleaseExpirationPeriod
2028-02
CY2020Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2019Q1 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1500000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
4378000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
6072000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
6375000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
6734000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
7100000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
24899000
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
55558000
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Trading Symbol
TradingSymbol
MGTA
CY2020Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2020Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Magenta Therapeutics, Inc.
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001690585
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39484341
CY2020Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q1 mgta Deferredofferingandredeemableconvertiblepreferred Share Issuance Cost Included In Accounts Payable Or Accrued Expenses
DeferredofferingandredeemableconvertiblepreferredShareIssuanceCostIncludedInAccountsPayableOrAccruedExpenses
-195000
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39588739
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39466254
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39454635
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39260532
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2020Q1 mgta Deferredofferingandredeemableconvertiblepreferred Share Issuance Cost Included In Accounts Payable Or Accrued Expenses
DeferredofferingandredeemableconvertiblepreferredShareIssuanceCostIncludedInAccountsPayableOrAccruedExpenses
0
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
7500000
CY2020Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2015-06-30
CY2020Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2020Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2019Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2020Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2019Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q1 us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
In May 2018, the Company entered into a sublease for up to approximately 69,000 square feet of office and laboratory space in Cambridge, Massachusetts. The sublease was amended effective March 2019 to increase the lease payments over the lease term and to increase the sublandlord-funded tenant improvements. The sublease is subject and subordinate to a prime lease between the sublandlord and the prime landlord. The term of the sublease commenced in June 2018 and expires in February 2028. The sublandlord has the right to terminate the sublease after five years.
CY2018Q2 mgta Sublease Termination Period
SubleaseTerminationPeriod
P5Y
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6005566
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5494971
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q1 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
1400000
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Use of Estimates </div></div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual for research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates. </div></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

Files In Submission

Name View Source Status
0001193125-20-135615-index-headers.html Edgar Link pending
0001193125-20-135615-index.html Edgar Link pending
0001193125-20-135615.txt Edgar Link pending
0001193125-20-135615-xbrl.zip Edgar Link pending
d898108d10q.htm Edgar Link pending
d898108dex311.htm Edgar Link pending
d898108dex312.htm Edgar Link pending
d898108dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mgta-20200331.xml Edgar Link completed
mgta-20200331.xsd Edgar Link pending
mgta-20200331_cal.xml Edgar Link unprocessable
mgta-20200331_def.xml Edgar Link unprocessable
mgta-20200331_lab.xml Edgar Link unprocessable
mgta-20200331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending